Potential roles of circulatory microRNAs in the onset and progression of renal and cardiac diseases: a focussed review for clinicians

References

• Turchinovich A, Samatov TR, Tonevitsky AG, et al. Circulating miRNAs: cell-cell communication function? Front Genet. 2013;4:119.
   PubMedGoogle Scholar
• Cullen BR. Transcription and processing of human microRNA precursors. Mol Cell. 2004;16(6):861–865.
   PubMed Web of Science ®Google Scholar
• Ricci Z, Romagnoli S, Ronco C. Cardiorenal syndrome. Crit Care Clin. 2021;37(2):335–347.
   PubMed Web of Science ®Google Scholar
• Ono K. 2017. MicroRNA-Linked heart disease and therapeutic potential. Translating MicroRNAs to the clinic. Amsterdam, Netherlands: Elsevier Inc.; p. 259–281.
   Google Scholar
• Leclercq M, Diallo AB, Blanchette M. Prediction of human miRNA target genes using computationally reconstructed ancestral mammalian sequences. Nucleic Acids Res. 2017;45(2):556–566.
   PubMed Web of Science ®Google Scholar
• Turchinovich A, Weiz L, Burwinkel B. Extracellular miRNAs: the mystery of their origin and function. Trends Biochem Sci. 2012;37(11):460–465.
   PubMed Web of Science ®Google Scholar
• Turchinovich A, Weiz L, Langheinz A, et al. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011;39(16):7223–7233.
   PubMed Web of Science ®Google Scholar
• Kumar S, Vijayan M, Bhatti JS, et al. MicroRNAs as peripheral biomarkers in aging and age-related diseases. Prog Mol Biol Transl Sci. 2017;146:47–94.
   PubMed Web of Science ®Google Scholar
• Valadi H, Ekström K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654–659.
   PubMed Web of Science ®Google Scholar
• Phuah NH, Nagoor NH. Regulation of MicroRNAs by natural agents: a new strategies in cancer therapies. Biomed Res Int. 2014;2014:804510.
   PubMed Web of Science ®Google Scholar
• Schickel R, Boyerinas B, Park SM, et al. MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene. 2008;27(45):5959–5974.
   PubMed Web of Science ®Google Scholar
• Wang K, Zhang S, Marzolf B, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA. 2009;106(11):4402–4407.
   PubMed Web of Science ®Google Scholar
• Wang WT, Chen YQ. Circulating miRNAs in cancer: from detection to therapy. J Hematol Oncol. 2014;7(1):1–9.
   PubMed Web of Science ®Google Scholar
• Kumar P, Dezso Z, MacKenzie C, et al. Circulating miRNA biomarkers for alzheimer’s disease. PLoS One. 2013;8(7):e69807.
   PubMed Web of Science ®Google Scholar
• Taïbi F, Metzinger-Le Meuth V, M’Baya-Moutoula E, et al. Possible involvement of microRNAs in vascular damage in experimental chronic kidney disease. Biochim Biophys Acta. 2014;1842(1):88–98.
   PubMed Web of Science ®Google Scholar
• Thum T, Gross C, Fiedler J, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008;456(7224):980–984.
   PubMed Web of Science ®Google Scholar
• Wang B, Herman-Edelstein M, Koh P, et al. E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-β. Diabetes. 2010;59(7):1794–1802.
   PubMed Web of Science ®Google Scholar
• Beermann J, Piccoli MT, Viereck J, et al. Non-coding RNAS in development and disease: background, mechanisms, and therapeutic approaches. Physiol Rev. 2016;96(4):1297–1325.
   PubMed Web of Science ®Google Scholar
• Ronco C, Bellasi A, Di Lullo L. Cardiorenal syndrome: an overview. Adv Chronic Kidney Dis. 2018;25(5):382–390.
   PubMed Web of Science ®Google Scholar
• Fabbri M, Paone A, Calore F, et al. MicroRNAs bind to toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci USA. 2012;109(31):E2110-6.
   PubMed Web of Science ®Google Scholar
• Fan PC, Chen CC, Peng CC, et al. A circulating miRNA signature for early diagnosis of acute kidney injury following acute myocardial infarction. J Transl Med. 2019;17(1):139.
   PubMed Web of Science ®Google Scholar
• Björklund M. Cell size homeostasis: metabolic control of growth and cell division. Biochim Biophys Acta Mol Cell Res. 2019;1866:409–417.
   PubMed Web of Science ®Google Scholar
• Ciesla M, Skrzypek K, Kozakowska M, et al. MicroRNAs as biomarkers of disease onset. Anal Bioanal Chem. 2011;401(7):2051–2061.
   PubMed Web of Science ®Google Scholar
• Matsuda A, Yan IK, Foye C, et al. MicroRNAs as paracrine signaling mediators in cancers and metabolic diseases. Best Pract Res Clin Endocrinol Metab. 2016;30(5):577–590.
   PubMed Web of Science ®Google Scholar
• Hüttenhofer A, Mayer G. Circulating miRNAs as biomarkers of kidney disease. Clin Kidney J. 2017;10(1):27–29.
   PubMed Web of Science ®Google Scholar
• Xu J, Zhao J, Evan G, et al. Circulating microRNAs: novel biomarkers for cardiovascular diseases. J Mol Med (Berl). 2012;90(8):865–875.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Zhang C. MicroRNA-21 in cardiovascular disease. J of Cardiovasc Trans Res. 2010;3(3):251–255.
   PubMed Web of Science ®Google Scholar
• Gupta SK, Bang C, Thum T. Circulating MicroRNAs as biomarkers and potential paracrine mediators of cardiovascular disease. Circ Cardiovasc Genet. 2010;3(5):484–488.
   PubMed Web of Science ®Google Scholar
• Rana I, Kompa AR, Skommer J, et al. Contribution of microRNA to pathological fibrosis in cardiorenal syndrome: impact of uremic toxins. Physiol Rep. 2015;3(4):e12371–e12371.
   Google Scholar
• Fichtlscherer S, Zeiher AM, Dimmeler S. Circulating MicroRNAs: biomarkers or mediators of cardiovascular diseases? Arterioscler Thromb Vasc Biol. 2011;31(11):2383–2390.
   PubMed Web of Science ®Google Scholar
• Méndez C, Ahlenstiel CL, Kelleher AD. Post-transcriptional gene silencing, transcriptional gene silencing and human immunodeficiency virus. World J Virol. 2015;4(3):219–244.
   PubMedGoogle Scholar
• Broughton JP, Lovci MT, Huang JL, et al. Pairing beyond the seed supports MicroRNA targeting specificity. Mol Cell. 2016;64(2):320–333.
   PubMed Web of Science ®Google Scholar
• Agarwal V, Bell GW, Nam JW, et al. Predicting effective microRNA target sites in mammalian mRNAs. eLife. 2015;4:e05005.
   PubMed Web of Science ®Google Scholar
• Ohrt T, Muetze J, Svoboda P, et al. Intracellular localization and routing of miRNA and RNAi pathway components. Curr Top Med Chem. 2012;12(2):79–88.
   PubMed Web of Science ®Google Scholar
• Roya K, et al. Stable association of RNAi machinery is conserved between the cytoplasm and nucleus of human cells. RNA. 2016;22(7):1085–1098.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–233.
   PubMed Web of Science ®Google Scholar
• Catalanotto C, Cogoni C, Zardo G. MicroRNA in control of gene expression: an overview of nuclear functions. Int J Mol Sci. 2016;17(10):1712.
   PubMed Web of Science ®Google Scholar
• Morris KV, Santoso S, Turner AM, et al. Bidirectional transcription directs both transcriptional gene activation and suppression in human cells. PLoS Genet. 2008;4(11):e1000258.
   PubMed Web of Science ®Google Scholar
• Katayama S, Tomaru Y, Kasukawa T, et al. Molecular biology: antisense transcription in the mammalian transcriptome. Science. 2005;309(5740):1564–1566.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zuo X, Yang B, et al. MicroRNA directly enhances mitochondrial translation during muscle differentiation. Cell. 2014;158(3):607–619.
   PubMed Web of Science ®Google Scholar
• Wei Y, Li L, Wang D, et al. Importin 8 regulates the transport of mature microRNAs into the cell nucleus. J Biol Chem. 2014;289(15):10270–10275.
   PubMed Web of Science ®Google Scholar
• Brameier M, Herwig A, Reinhardt R, et al. Human box C/D snoRNAs with miRNA like functions: expanding the range of regulatory RNAs. Nucleic Acids Res. 2011;39(2):675–686.
   PubMed Web of Science ®Google Scholar
• Yekta S, Shih IH, Bartel DP. MicroRNA-Directed cleavage of HOXB8 mRNA. Science. 2004;304(5670):594–596.
   PubMed Web of Science ®Google Scholar
• Hennino MF, Buob D, Van der Hauwaert C, et al. MiR-21-5p renal expression is associated with fibrosis and renal survival in patients with IgA nephropathy. Sci Rep. 2016;6(1):1–9.
   PubMed Web of Science ®Google Scholar
• Wang J, Gao Y, Ma M, et al. Effect of miR-21 on renal fibrosis by regulating MMP-9 and TIMP1 in kk-ay diabetic nephropathy mice. Cell Biochem Biophys. 2013;67(2):537–546.
   PubMed Web of Science ®Google Scholar
• Lange T, Artelt N, Kindt F, et al. MiR-21 is up-regulated in urinary exosomes of chronic kidney disease patients and after glomerular injury. J Cell Mol Med. 2019;23(7):4839–4843.
   PubMed Web of Science ®Google Scholar
• Lorenzen JM, Kaucsar T, Schauerte C, et al. MicroRNA-24 antagonism prevents renal ischemia reperfusion injury. J Am Soc Nephrol. 2014;25(12):2717–2729.
   PubMed Web of Science ®Google Scholar
• Brigant B, Metzinger-Le Meuth V, Massy ZA, et al. Serum microRNAs are altered in various stages of chronic kidney disease: a preliminary study. Clin Kidney J. 2017;10(1):30–37.
   PubMed Web of Science ®Google Scholar
• Barutta F, Tricarico M, Corbelli A, et al. Urinary exosomal MicroRNAs in incipient diabetic nephropathy. PLoS One. 2013;8(11):e73798.
   PubMed Web of Science ®Google Scholar
• Delić D, Eisele C, Schmid R, et al. Urinary exosomal miRNA signature in type II diabetic nephropathy patients. PLoS One. 2016;11(3):e0150154.
   PubMed Web of Science ®Google Scholar
• Güçlü A, Koçak C, Koçak FE, et al. Micro RNA-320 as a novel potential biomarker in renal ischemia reperfusion. Ren Fail. 2016;38(9):1468–1475.
   PubMed Web of Science ®Google Scholar
• Qin LY, Wang MX, Zhang H. MiR-133a alleviates renal injury caused by sepsis by targeting BNIP3L. Eur Rev Med Pharmacol Sci. 2020;24(5):2632–2639.
   PubMed Web of Science ®Google Scholar
• Saikumar J, Hoffmann D, Kim T-M, et al. Expression, circulation, and excretion profile of microRNA-21, -155, and -18a following acute kidney injury. Toxicol Sci. 2012;129(2):256–267.
   PubMed Web of Science ®Google Scholar
• Zhang W, Li X, Tang Y, et al. MiR-155-5p implicates in the pathogenesis of renal fibrosis via targeting SOCS1 and SOCS6. Oxid Med Cell Longevity. 2020;2020:1–11.
   Web of Science ®Google Scholar
• Lv LL, Cao YH, Ni HF, et al. MicroRNA-29c in urinary exosome/microvesicle as a biomarker of renal fibrosis. Am J Physiol Renal Physiol. 2013;305(8):F1220–F1227.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Ji R, Yue J, et al. MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a pole in cardiac hypertrophy? Am J Pathol. 2007;170(6):1831–1840.
   PubMed Web of Science ®Google Scholar
• Thum T, Galuppo P, Wolf C, et al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation. 2007;116(3):258–267.
   PubMed Web of Science ®Google Scholar
• Xu L, Tian L, Yan Z, et al. Diagnostic and prognostic value of miR-486-5p, miR-451a, miR-21-5p and monocyte to high-density lipoprotein cholesterol ratio in patients with acute myocardial infarction. Heart Vessels. 2023;38(3):318–331.
   PubMed Web of Science ®Google Scholar
• van Rooij E, Sutherland LB, Liu N, et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A. 2006;103(48):18255–18260.
   PubMed Web of Science ®Google Scholar
• Lakhani HV, Khanal T, Gabi A, et al. Developing a panel of biomarkers and miRNA in patients with myocardial infarction for early intervention strategies of heart failure in west Virginian population. PLoS One. 2018;13(10):e0205329.
   PubMed Web of Science ®Google Scholar
• Fiedler J, Jazbutyte V, Kirchmaier BC, et al. MicroRNA-24 regulates vascularity after myocardial infarction. Circulation. 2011;124(6):720–730.
   PubMed Web of Science ®Google Scholar
• Zhang M, Cheng YJ, Sara JD, et al. Circulating microRNA-145 is associated with acute myocardial infarction and heart failure. Chin Med J (Engl). 2017;130(1):51–56.
   PubMed Web of Science ®Google Scholar
• Wang H, Lian X, Gao W, et al. Long noncoding RNA H19 suppresses cardiac hypertrophy through the MicroRNA-145-3p/SMAD4 axis. Bioengineered. 2022;13(2):3826–3839.
   PubMed Web of Science ®Google Scholar
• Chen C, Wang Y, Yang S, et al. MiR-320a contributes to atherogenesis by augmenting multiple risk factors and down-regulating SRF. J Cell Mol Med. 2015;19(5):970–985.
   PubMed Web of Science ®Google Scholar
• Goren Y, Kushnir M, Zafrir B, et al. Serum levels of microRNAs in patients with heart failure. Eur J Heart Fail. 2012;14(2):147–154.
   PubMed Web of Science ®Google Scholar
• Habibi P, Alihemmati A, Nasirzadeh M, et al. Involvement of microRNA-133 and-29 in cardiac disturbances in diabetic ovariectomized rats. Iran J Basic Med Sci. 2016;19(11):1177–1185.
   PubMed Web of Science ®Google Scholar
• Danowski N, Manthey I, Jakob HG, et al. Decreased expression of miR-133a but not of miR-1 is associated with signs of heart failure in patients undergoing coronary bypass surgery. Cardiology (Switzerland). 2013;125(2):125–130.
   PubMed Web of Science ®Google Scholar
• Boštjančič E, Zidar N, Štajer D, et al. MicroRNAs miR-1, miR-133a, miR-133b and miR-208 are dysregulated in human myocardial infarction. Cardiology. 2010;115(3):163–169.
   PubMed Web of Science ®Google Scholar
• Zhang B, Li B, Qin F, et al. Expression of serum microRNA-155 and its clinical importance in patients with heart failure after myocardial infarction. J Int Med Res. 2019;47(12):6294–6302.
   PubMed Web of Science ®Google Scholar
• Git A, Dvinge H, Salmon-Divon M, et al. Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression. RNA. 2010;16(5):991–1006.
   PubMed Web of Science ®Google Scholar
• Trevino V, Falciani F, Barrera-Saldaña HA. DNA microarrays: a powerful genomic tool for biomedical and clinical research. Mol Med. 2007;13(9–10):527–541.
   PubMed Web of Science ®Google Scholar
• Romaine S, Charchar PR, Samani FJ, et al. Circulating microRNAs and hypertension - From new insights into blood pressure regulation to biomarkers of cardiovascular risk. Curr Opin Pharmacol. 2016;27:1–7.
   PubMed Web of Science ®Google Scholar
• Li N, Ma J, Guarnera MA, et al. Digital PCR quantification of miRNAs in sputum for diagnosis of lung cancer. J Cancer Res Clin Oncol. 2014;140(1):145–150.
   PubMed Web of Science ®Google Scholar
• Miotto E, Saccenti E, Lupini L, et al. Quantification of circulating miRNAs by droplet digital PCR: comparison of EvaGreen- and TaqMan-based chemistries. Cancer Epidemiol Biomarkers Prev. 2014;23(12):2638–2642.
   PubMed Web of Science ®Google Scholar
• Meister G, Landthaler M, Patkaniowska A, et al. Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol Cell. 2004;15(2):185–197.
   PubMed Web of Science ®Google Scholar
• Du J, Cao X, Zou L, et al. MicroRNA-21 and risk of severe acute kidney injury and poor outcomes after adult cardiac surgery. PLoS One. 2013;8(5):e63390.
   PubMed Web of Science ®Google Scholar
• Kumar D, Narang R, Sreenivas V, et al. Circulatory miR-133b and miR-21 as novel biomarkers in early prediction and diagnosis of coronary artery disease. Genes. 2020;11(2):164.
   PubMed Web of Science ®Google Scholar
• Markou A, Zavridou M, Lianidou ES. MiRNA-21 as a novel therapeutic target in lung cancer. Lung Cancer. 2016;7:19–27.
   Google Scholar
• Zhong X, Chung ACK, Chen HY, et al. MiR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes. Diabetologia. 2013;56(3):663–674.
   PubMed Web of Science ®Google Scholar
• Liu XJ, Hong Q, Wang Z, et al. MicroRNA21 promotes interstitial fibrosis via targeting DDAH1: a potential role in renal fibrosis. Mol Cell Biochem. 2016;411(1–2):181–189.
   PubMed Web of Science ®Google Scholar
• Dickhout JG, Carlisle RE, Austin, RC. Interrelationship between cardiac hypertrophy, heart failure, and chronic kidney disease: endoplasmic reticulum stress as a mediator of pathogenesis. Circ Res. 2011;108(5):629–642.
   PubMed Web of Science ®Google Scholar
• Bonneux L, Barendregt JJ, Meeter K, et al. Estimating clinical morbidity due to ischemic heart disease and congestive heart failure: the future rise of heart failure. Am J Public Health. 1994;84(1):20–28.
   PubMed Web of Science ®Google Scholar
• Robinson S, Follo M, Haenel D, et al. Chip-based digital PCR as a novel detection method for quantifying microRNAs in acute myocardial infarction patients article. Acta Pharmacol Sin. 2018;39(7):1217–1227.
   PubMed Web of Science ®Google Scholar
• Sluijter JPG, Verhage V, Deddens JC, et al. Microvesicles and exosomes for intracardiac communication. Cardiovasc Res. 2014;102(2):302–311.
   PubMed Web of Science ®Google Scholar
• Deng X, Liu Y, Luo M, et al. Circulating miRNA-24 and its target YKL-40 as potential biomarkers in patients with coronary heart disease and type 2 diabetes mellitus. Oncotarget. 2017;8(38):63038–63046.
   PubMedGoogle Scholar
• Wang J, Huang W, Xu R, et al. MicroRNA-24 regulates cardiac fibrosis after myocardial infarction. J Cell Mol Med. 2012;16(9):2150–2160.
   PubMed Web of Science ®Google Scholar
• Zernecke A, Bidzhekov K, Noels H, et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal. 2009;2(100):ra81.
   PubMed Web of Science ®Google Scholar
• Kaltsas E, Chalikias G, Tziakas D. The incidence and the prognostic impact of acute kidney injury in acute myocardial infarction patients: current preventive strategies. Cardiovasc Drugs Ther. 2018;32(1):81–98.
   PubMed Web of Science ®Google Scholar
• Qian L, Van Laake LW, Huang Y, et al. miR-24 inhibits apoptosis and represses bim in mouse cardiomyocytes. J Exp Med. 2011;208(3):549–560.
   PubMed Web of Science ®Google Scholar
• Dimmeler S, Zeiher AM. Circulating microRNAs: novel biomarkers for cardiovascular diseases? Eur Heart J. 2010;31(22):2705–2707.
   PubMed Web of Science ®Google Scholar
• Xiao M, Li J, Li W, et al. MicroRNAs activate gene transcription epigenetically as an enhancer trigger. RNA Biol. 2017;14(10):1326–1334.
   PubMed Web of Science ®Google Scholar
• Hoekstra M, van der Lans CAC, Halvorsen B, et al. The peripheral blood mononuclear cell microRNA signature of coronary artery disease. Biochem Biophys Res Commun. 2010;394(3):792–797.
   PubMed Web of Science ®Google Scholar
• Yan L, Guo N, Cao Y, et al. miRNA-145 inhibits myocardial infarction-induced apoptosis through autophagy via Akt3/mTOR signaling pathway in vitro and in vivo. Int J Mol Med. 2018;42(3):1537–1547.
   PubMed Web of Science ®Google Scholar
• Higashi K, Yamada Y, Minatoguchi S, et al. MicroRNA-145 repairs infarcted myocardium by accelerating cardiomyocyte autophagy. Am J Physiol Heart Circ Physiol. 2015;309(11):H1813–H1826.
   PubMed Web of Science ®Google Scholar
• Ma MKM, Yung S, Chan, TM MTOR inhibition and kidney diseases. Transplantation. 2018;102(1):S32–S40.
   PubMed Web of Science ®Google Scholar
• Xu CN, Kong LH, Ding P, et al. Melatonin ameliorates pressure overload-induced cardiac hypertrophy by attenuating Atg5-dependent autophagy and activating the Akt/mTOR pathway. Biochim Biophys Acta Mol Basis Dis. 2020;1866(10):165848.
   PubMed Web of Science ®Google Scholar
• Cordes KR, Sheehy NT, White MP, et al. MiR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature. 2009;460(7256):705–710.
   PubMed Web of Science ®Google Scholar
• Gao H, Guddeti RR, Matsuzawa Y, et al. Plasma levels of microRNA-145 are associated with severity of coronary artery disease. PLoS One. 2015;10(5):e0123477.
   PubMed Web of Science ®Google Scholar
• Chen Y, Sun Y, Rao Q, et al. Androgen receptor (AR) suppresses miRNA-145 to promote renal cell carcinoma (RCC) progression independent of VHL status. Oncotarget. 2015;6(31):31203–31215.
   PubMedGoogle Scholar
• Du H, Zhao Y, Yin Z, et al. The role of miR-320 in glucose and lipid metabolism disorder-associated diseases. Int J Biol Sci. 2021;17(2):402–416.
   PubMed Web of Science ®Google Scholar
• Lorenzen JM, Kielstein JT, Hafer C, et al. Circulating miR-210 predicts survival in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol. 2011;6(7):1540–1546.
   PubMed Web of Science ®Google Scholar
• Ren XP, Wu J, Wang X, et al. MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20. Circulation. 2009;119(17):2357–2366.
   PubMed Web of Science ®Google Scholar
• Wang QG, Cheng B, He YZ, et al. miR-320a in serum exosomes promotes myocardial fibroblast proliferation via regulating the PIK3CA/Akt/mTOR signaling pathway in HEH2 cells. Exp Ther Med. 2021;22(2):1–14.
   Web of Science ®Google Scholar
• Chai J, Tarnawski AS. Serum response factor: discovery, biochemistry, biological roles and implications for tissue injury healing. J Physiol Pharmacol. 2002;53:147–157.
   PubMed Web of Science ®Google Scholar
• Van Dam EM, Govers R, James, DE. Akt activation is required at a late stage of insulin-induced GLUT4 translocation to the plasma membrane. Mol Endocrinol. 2005;19(4):1067–1077.
   PubMedGoogle Scholar
• Ling HY, Ou HS, Feng SD, et al. Changes in microRNA (miR) profile and effects of mir-320 in insulin-resistant 3t3-l1 adipocytes. Clin Exp Pharmacol Physiol. 2009;36(9):e32–e39.
   PubMed Web of Science ®Google Scholar
• Yu H, Tigchelaar W, Koonen DPY, et al. AKIP1 expression modulates mitochondrial function in rat neonatal cardiomyocytes. PLoS One. 2013;8(11):e80815.
   PubMed Web of Science ®Google Scholar
• Hartmann D, Thum T. MicroRNAs and vascular (dys) function. Vascul Pharmacol. 2011;55(4):92–105.
   PubMed Web of Science ®Google Scholar
• Yu H, Lu Y, Li Z, et al. microRNA-133: expression, function and therapeutic potential in muscle diseases and cancer. Curr Drug Targets. 2014;15(9):817–828.
   PubMed Web of Science ®Google Scholar
• Zhu L, Xiang M. The correlations of circulating microRNA-133a with the risk and severity of coronary heart disease. Int J Clin Exp Med. 2017;10:972–978.
   Web of Science ®Google Scholar
• Parthenakis FI, Marketou ME, Kontaraki JE, et al. Comparative microRNA profiling in relation to urinary albumin excretion in newly diagnosed hypertensive patients. J Hum Hypertens. 2016;30(11):685–689.
   PubMed Web of Science ®Google Scholar
• Loeser H, Von Brandenstein M, Herschung A, et al. ET-1 induced downregulation of MRP2 via miRNA 133a-a marker for tubular nephrotoxicity? Am J Nephrol. 2015;41(3):191–199.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Zhao J, Tuazon JP, et al. MicroRNA-133a and myocardial infarction. Cell Transplant. 2019;28(7):831–838.
   PubMed Web of Science ®Google Scholar
• De Rosa S, Fichtlscherer S, Lehmann R, et al. Transcoronary concentration gradients of circulating MicroRNAs. Circulation. 2011;124(18):1936–1944.
   PubMed Web of Science ®Google Scholar
• Wang GK, Zhu JQ, Zhang JT, et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J. 2010;31(6):659–666.
   PubMed Web of Science ®Google Scholar
• Gidlöf O, Andersson P, Van Der Pals J, et al. Cardiospecific microRNA plasma levels correlate with troponin and cardiac function in patients with ST elevation myocardial infarction, are selectively dependent on renal elimination, and can be detected in urine samples. Cardiology. 2011;118(4):217–226.
   PubMed Web of Science ®Google Scholar
• Sang HQ, Jiang ZM, Zhao QP, et al. MicroRNA-133a improves the cardiac function and fibrosis through inhibiting akt in heart failure rats. Biomed Pharmacother. 2015;71:185–189.
   PubMed Web of Science ®Google Scholar
• Muraoka N, Yamakawa H, Miyamoto K, et al. MiR‐133 promotes cardiac reprogramming by directly repressing Snai1 and silencing fibroblast signatures. EMBO J. 2014;33(14):1565–1581.
   PubMed Web of Science ®Google Scholar
• Cao RY, Li Q, Miao Y, et al. The emerging role of MicroRNA-155 in cardiovascular diseases. Biomed Res Int. 2016;2016:1–5.
   Web of Science ®Google Scholar
• Faraoni I, Antonetti FR, Cardone J, et al. miR-155 gene: a typical multifunctional microRNA. Biochim Biophys Acta Mol Basis Dis. 2009;1792:497–505.
   PubMed Web of Science ®Google Scholar
• Wang H, Peng W, Shen X, et al. Circulating levels of inflammation-associated mir-155 and endothelial-enriched mir-126 in patients with end-stage renal disease. Braz J Med Biol Res. 2012;45(12):1308–1314.
   PubMed Web of Science ®Google Scholar
• Li Y, Sun Y, Liu F, et al. Norcantharidin inhibits renal interstitial fibrosis by blocking the tubular Epithelial-Mesenchymal transition. PLoS One. 2013;8(6):e66356.
   PubMed Web of Science ®Google Scholar
• Trusinskis K, Lapsovs M, Paeglite S, et al. Plasma circulating microRNAs in patients with stable coronary artery disease - impact of different cardiovascular risk profiles and glomerular filtration rates. J Clin Transl Res. 2021;7(2):270–276.
   PubMedGoogle Scholar
• Andreou I, Sun X, Stone PH, et al. miRNAs in atherosclerotic plaque initiation, progression, and rupture. Trends Mol Med. 2015;21(5):307–318.
   PubMed Web of Science ®Google Scholar
• Bruen R, Fitzsimons S, Belton O. MiR-155 in the resolution of atherosclerosis. Front Pharmacol. 2019;10:463.
   PubMed Web of Science ®Google Scholar
• Hao L, Wang XG, Cheng JD, et al. The up-regulation of endothelin-1 and down-regulation of miRNA-125a-5p, -155, and -199a/b-3p in human atherosclerotic coronary artery. Cardiovasc Pathol. 2014;23(4):217–223.
   PubMed Web of Science ®Google Scholar
• Tian FJ, An LN, Wang GK, et al. Elevated microRNA-155 promotes foam cell formation by targeting HBP1 in atherogenesis. Cardiovasc Res. 2014;103(1):100–110.
   PubMed Web of Science ®Google Scholar
• Lekawanvijit S, Kompa AR, Zhang Y, et al. Myocardial infarction impairs renal function, induces renal interstitial fibrosis, and increases renal KIM-1 expression: implications for cardiorenal syndrome. Am J Physiol Heart Circulat Physiol. 2012;302(9):H1884–H1893.
   PubMed Web of Science ®Google Scholar
• Zununi Vahed S, Poursadegh Zonouzi A, Ghanbarian H, et al. Differential expression of circulating miR-21, miR-142-3p and miR-155 in renal transplant recipients with impaired graft function. Int Urol Nephrol. 2017;49(9):1681–1689.
   PubMed Web of Science ®Google Scholar
• Culleton BF, Hemmelgarn BR. Is chronic kidney disease a cardiovascular disease risk factor? Semin Dial. 2003;16(2):95–100.
   PubMed Web of Science ®Google Scholar
• Corsten MF, Dennert R, Jochems S, et al. Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet. 2010;3(6):499–506.
   PubMed Web of Science ®Google Scholar
• Qin W, Chung ACK, Huang XR, et al. TGF-β/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J Am Soc Nephrol. 2011;22(8):1462–1474.
   PubMed Web of Science ®Google Scholar
• Jiang L, Zhou Y, Xiong M, et al. Sp1 mediates microRNA-29c-regulated type I collagen production in renal tubular epithelial cells. Exp Cell Res. 2013;319(14):2254–2265.
   PubMed Web of Science ®Google Scholar
• Fang Y, Yu X, Liu Y, et al. miR-29C is downregulated in renal interstitial fibrosis in humans and rats and restored by HIF-α activation. Am J Physiol Renal Physiol. 2013;304(10):F1274–F1282.
   PubMed Web of Science ®Google Scholar
• Maurer B, Stanczyk J, Jüngel A, et al. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum. 2010;62(6):1733–1743.
   PubMed Web of Science ®Google Scholar
• Samanta S, Balasubramanian S, Rajasingh S, et al. MicroRNA: a new therapeutic strategy for cardiovascular diseases. Trends Cardiovasc Med. 2016;26(5):407–419.
   PubMed Web of Science ®Google Scholar
• Mohamed SE, Ghanoum RA, EL-Abed SF. MicroRNA29-a as diabetic nephropathy biomarker in diabetic patients (type 2). Med J Cairo Univ. 2019;87:2593–2597.
   Google Scholar
• Liu Y, Taylor NE, Lu L, et al. Renal medullary MicroRNAs in dahl salt-sensitive rats: miR-29b regulates several collagens and related genes. Hypertension. 2010;55(4):974–982.
   PubMed Web of Science ®Google Scholar